Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $11.45, but opened at $10.95. Mesoblast shares last traded at $10.95, with a volume of 49,100 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MESO shares. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Stock Down 3.1 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $7.93.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors have recently modified their holdings of MESO. GAMMA Investing LLC grew its holdings in Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after purchasing an additional 1,663 shares during the period. Signaturefd LLC increased its holdings in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares in the last quarter. Perkins Coie Trust Co acquired a new position in Mesoblast during the second quarter worth $68,000. Pine Valley Investments Ltd Liability Co purchased a new position in Mesoblast during the second quarter valued at $80,000. Finally, Rathbones Group PLC acquired a new stake in shares of Mesoblast in the second quarter valued at about $95,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.